Jonathan Kalinowski

Jonathan Kalinowski

Auto-generated profile, based on publicly available information

Jonathan Kalinowski

Medical Physics Unit Department of Oncology Faculty of Medicine McGill University Montréal Quebec Canada

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2025 in Medical Physics
Verified
Journal Article
Open access
BMBjörn Morén
Björn Morén
ATAlana Thibodeau‐Antonacci
Alana Thibodeau‐Antonacci
JKJonathan Kalinowski
Jonathan Kalinowski
SEShirin A. Enger
Shirin A. Enger
Background: Intensity‐modulated brachytherapy (IMBT) employs rotating high‐Z shields during treatment to decrease radiation in certain directions and conform the dose distribution to the target volume. Prototypes for dynamic IMBT have been proposed for prostate, cervical, and rectal cancer. Purpose: We considered two shielded applicators for IMBT rectal cancer treatment and investigated how rotational uncertainties in the shield angle and translational uncertainties in the source position affect plan evaluation criteria. Methods: The effect of rotational errors of , and , and translational errors of 1, 2 and 3 mm on evaluation criteria were investigated for shields with and emission windows. Further, a robust optimization approach based on quadratic penalties that includes scenarios with errors was proposed. The extent to which dosimetric effects of positional errors can be mitigated with this model was evaluated compared to a quadratic penalty model without scenarios with errors. A retrospective rectal cancer data set of ten patients was included in this study. Treatment planning was performed using the Monte Carlo‐based treatment planning system, RapidBrachyMCTPS. Results: For the largest investigated rotational error of , the clinical target volume remained, on average, within of the result without error, while the contralateral healthy rectal wall experienced an increase in the mean , , and of , , and for the shield and of 32%, 9%, and 2% for the shield. For translational errors of mm, there were increases in dosimetric indices for both the superior (sup) and inferior (inf) dose spill regions. Specifically, for the shield, the , , and increased by , , and , respectively, for the sup region, and by , , and , respectively, for the inf region. Similar results were obtained with the shield. Overall, the robust and traditional models had similar results. However, the number of active dwell positions obtained with the robust model was larger, and the longest dwell time was shorter. Conclusions: We have quantified the effect of rotational shield and translational source errors of various magnitudes on evaluation criteria for rectal IMBT. The robust optimization approach was generally not able to mitigate positional errors. However, it resulted in more homogeneous dwell times, which can be beneficial in conventional high‐dose‐rate brachytherapy to avoid hot spots around specific dwell positions.

15 July 2025 in Medical Physics
Verified
Journal Article
Open access
MDMirta Dumančić
Mirta Dumančić
JKJonathan Kalinowski
Jonathan Kalinowski
VDVictor D. Diaz‐Martinez
Victor D. Diaz‐Martinez
JLJoanna Li
Joanna Li
BBBehnaz Behmand
Behnaz Behmand
SEShirin A. Enger
Shirin A. Enger
Background: Radiobiological data suggests variations in relative biological effectiveness (RBE) between clinically used photon‐based sources. A microdosimetric formalism using Monte Carlo (MC) methods can mechanistically describe the photon RBE. Experimentally derived RBE based on DNA double‐strand breaks () has been shown to scale with the microdosimetry quantity dose‐mean lineal energy (). Purpose: To calculate microdosimetric spectra for clinically relevant photon sources, spanning from soft x‐rays produced by a 50 kVp x‐ray source through various brachytherapy sources up to a 6 MV medical linac. Furthermore, we investigated the correlation between and of different photon sources. Methods: Photon sources simulated include low‐energy x‐rays (50 kVp), orthovoltage x‐rays (225 kVp), high‐dose‐rate brachytherapy sources ( 75 Se, 192 Ir and 60 Co), and a 6 MV medical linac. Secondary electron spectra at the cellular level were calculated for in vitro cell irradiation setups using Geant4 MC‐based packages, RapidBrachyMCTPS and RapidExternalBeam. The obtained spectra were used in MicroDose, a microdosimetry simulation software, to obtain microdosimetric quantities, including single‐event lineal energy () and specific energy () spectra, and dose‐mean and frequency‐mean quantities (, , , ). Uniform spherical targets (1–14 radius) and realistic HeLa and PC3 cell nucleus models were simulated using cell size data obtained from literature and nuclei size data from confocal microscopy imaging. Radiobiological experiments using foci quantified DNA double‐strand breaks for HeLa and PC3 cells after irradiations with 50 and 225 kVp, 192 Ir, and 6 MV linac, and was determined using 225 kVp as the reference. Results: The calculated () is within the 3.5–1.2 keV/ range (1.8–0.2 keV/) for 1 simulated target size between the lowest energy 50 kVp x‐ray source and the highest energy 6 MV linac source, respectively. For the HeLa and PC3 cell nuclei models based on microscopy data, () spans from 1.6 to 0.6 keV/ (0.7 to 0.2 keV/). When compared between different target sizes, () ranges from 3.5 to 1.0 (1.8–0.4) keV/ between 1 and 10 radius targets for the 50 kVp x‐ray source. A smaller change is observed for 6 MV linac, ranging from 1.2 to 0.5 keV/ and 0.23 to 0.22 keV/ for and , respectively. For the simulated 75 Se source currently under investigation, the calculated values are 11%–24% higher relative to those of 192 Ir in the range of target sizes between 1 and 14 in radius. for HeLa cells was 1.40.7 for 50 kVp x‐rays, 0.50.2 for 192 Ir, and 0.70.4 for 6 MV linac irradiations. For PC3 cells, was 1.30.6, 0.80.4 and 0.50.3 for 50 kVp, 192 Ir and 6 MV linac, respectively. Measured values are consistent with ratios of the corresponding photon sources for HeLa and PC3 nucleus models. Conclusions: Microdosimetric spectra strongly depend on the simulated energy of photon sources and target size, with and decreasing by a factor of 2–3 between diagnostic 50 kVp and 6 MV therapeutic x‐rays for target sizes from 1–14 in radius. The early damage indicates this stochastic change in energy density between various photon sources as the yields of foci per nucleus scale with of the source.

9 September 2025 in Medical Physics
Verified
Journal Article
Open access
JKJonathan Kalinowski
Jonathan Kalinowski
OTOren Tal
Oren Tal
JRJake Reid
Jake Reid
JMJohn Munro
John Munro
MMMatthew Moran
Matthew Moran
SEShirin A. Enger
Shirin A. Enger
Background: 75 Se ( 120 days, 215 keV) offers advantages over 192 Ir ( 74 days, 360 keV) as a high dose rate brachytherapy source due to its lower gamma energy and longer half‐life. Despite its widespread use in industrial gamma radiography, a 75 Se brachytherapy source has yet to be manufactured. Purpose: A novel 75 Se‐based source design with a vanadium diselenide core, titled the SeCure source, was proposed. This study aimed to evaluate the feasibility of this source design for dosimetry and manufacturability purposes and to develop an activated prototype source. Methods: The source was modeled and integrated into the Monte Carlo‐based treatment planning system RapidBrachyMCTPS, where its TG‐43U1 parameters, photon spectrum, and broad beam first half‐value layers (HVL 1 ) and tenth‐value layers (TVL 1 ) in lead, tungsten, and concrete were calculated. A prototype source was manufactured, and the vanadium diselenide content of the capsule was verified with neutron radiography. The source was then activated to a nominal activity of mCi at the McMaster Nuclear Reactor. The activity was measured with two separate dose calibrators. Gamma spectroscopy was used to characterize any activated radioactive contaminants in the source, and wipe testing was performed to check for any leakage of 75 Se from the encapsulation. Results: The SeCure source's TG‐43U1 parameters were computed, showing that times the activity of 75 Se is required relative to 192 Ir to achieve the same dose rate in water at (1 cm, 90). The mean spectral energy of the source is keV, resulting in reduced first half‐value and tenth‐value layers relative to 192 Ir in attenuating materials. For example, the was reduced from mm to mm in lead, from mm to mm in tungsten, and from mm to mm in concrete. The activated source achieved the desired activity, indicated as mCi and mCi at the end of irradiation on the two dose calibrators. All identified radionuclide contaminants decaying below of the 75 Se activity after 5 days post‐irradiation. Wipe testing only identified radioactive contaminants present in activated titanium, with only mCi of detected 72 h post‐irradiation, indicating that the integrity of the encapsulation was maintained. Conclusions: The SeCure design possesses the dosimetric, spectral, and physical properties necessary for a feasible high dose rate brachytherapy source. Next, manufacturing of a high‐activity SeCure source will be pursued.

16 June 2026 in Physics in Medicine & Biology
Verified
Journal Article
Open access
JKJonathan Kalinowski
Jonathan Kalinowski
HJHossein Jafarzadeh
Hossein Jafarzadeh
FFFarhood Farahnak
Farhood Farahnak
SEShirin Abbasinejad Enger
Shirin Abbasinejad Enger
Objective. RapidBrachyMCTPS is a Monte Carlo (MC)-based treatment planning system for advanced brachytherapy dosimetry applications. In this work, we present the latest updates in RapidBrachyMCTPS v3.0 and benchmark its dose calculations against published guidelines. Approach. RapidBrachyMCTPS v3.0 introduces a major redevelopment of RapidBrachyMC, its underlying MC dose calculation engine. Simulation times were reduced, greater user control over simulation geometry was enabled, and material definitions were greatly simplified and standardized. Test cases developed by the working group on model-based dose calculation algorithms in brachytherapy (WGDCAB) were used to benchmark dose calculation accuracy and quantify improvements in simulation efficiency relative to v2.0. Main results. For four water phantom-based WGDCAB test cases, mean and root-mean-square dose differences between reference data and RapidBrachyMCTPS v3.0-calculated dose distributions were within the estimated total uncertainty budget of 0.4%. Target structure dose-volume histogram metrics for site-specific WGDCAB test cases, one for gynecological tandem and ring brachytherapy and the other for interstitial breast brachytherapy, showed generally good agreement, within 0.01 Gy or 0.10 percentage points, with the same metrics calculated from reference dose distributions. Observed simulation run times for test cases were on average between 1.63 ± 0.02 and 1.66 ± 0.03 times faster than v2.0 without an applicator model and between 1.45 ± 0.01 and 1.91 ± 0.02 times faster with an applicator model, depending on the applicator modeling scheme used. Significance. RapidBrachyMCTPS v3.0 was well-validated to deliver fast, accurate MC dose calculations alongside robust treatment planning capabilities. It remains freely available to the research community.